Isatuximab‐carfilzomib‐dexamethasone immediately after failing of the quadruplet Daratumumab‐bortezomib‐lenalidomide‐dexamethasone (Dara‐VRD): Striking response with no washout in a newly diagnosed multiple myeloma

Podobne knjige/članki

• Isatuximab‐carfilzomib‐dexamethasone immediately after failing of the quadruplet Daratumumab‐bortezomib‐lenalidomide‐dexamethasone (Dara‐VRD): Striking response with no washout in a newly diagnosed multiple myeloma
  od: Juan José Gil‐Fernández, et al.
  Izdano: (2024-01-01)
• Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
  od: A P Dubey, et al.
  Izdano: (2020-01-01)
• Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
  od: Sonia Morè, et al.
  Izdano: (2020-11-01)
• CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
  od: Hongjie Wang, et al.
  Izdano: (2024-12-01)
• Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study
  od: Faouzi Djebbari, et al.
  Izdano: (2022-12-01)